2023-503382-29-00已完成3 期
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)
Alnylam Pharmaceuticals Inc.4 个研究点 分布在 4 个国家目标入组 7 人开始时间: 2023年5月25日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 7
- 试验地点
- 4
- 主要终点
- Cohort A: Percent change in plasma oxalate from Baseline to Month 6
研究概览
简要总结
Cohort A • Evaluate the effect of lumasiran on plasma oxalate in patients who are not on dialysis therapy Cohort B • Evaluate the effect of lumasiran on plasma oxalate levels in patients who are on dialysis therapy
研究设计
- 分配方式
- Randomized
- 主要目的
- A Single Arm Study
- 盲法
- None
入排标准
- 年龄范围
- 0 years 至 64 years（0-17 Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Cohort A and B: Have reached at least 37 weeks estimated gestational age (full-term infant) at consent (or assent)
- •Documentation or confirmation of PH1 as determined by genetic analysis prior to initial dosing.
- •Patients with eGFR ≤45 mL/min/1.73 m2 as calculated by the MDRD formula if ≥18 years or Schwartz Bedside Formula if ≥12 months to <18 years, or patients <12 months of age with serum creatinine that is considered elevated for age at consent.
- •The mean of the three most recent screening plasma oxalate samples collected prior to Day 1 is ≥20 μmol/L. In Cohort B, these 3 collections may include the first pre-dialysis sample from each plasma oxalate profile.
- •If taking therapeutic vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days before consent, and is able and willing to remain on this stable regimen until at least the Month 6 visit. Dose adjustments for interval weight gain are acceptable.
- •Patient is willing and able to comply with the study requirements and to provide written informed consent. In the case of patients under the age of legal consent, the legal guardian(s) must provide informed consent and the patient should provide assent per local and national requirements.
- •Cohort B Only 1: On a stable hemodialysis regimen for at least 4 weeks prior to Screening plasma oxalate assessment; able and willing to maintain this regimen through Month 6 visit, with changes to dialysis regimen permitted only when medically indicated.
排除标准
- •Has any of the following laboratory parameter assessments at Screening: a. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2× ULN for age b. Total bilirubin >1.5×ULN. Patients with elevated total bilirubin that is secondary to documented Gilbert's syndrome are eligible if the total bilirubin is <2× ULN c. International normalized ratio (INR) >1.5 for patients not on anticoagulants. Patients on oral anticoagulants (eg, warfarin) with an INR <3.5 will be allowed. d. Hemoglobin <8.0 mg/dL
- •Patients with a previous kidney transplant who are currently receiving immunosuppression to prevent transplant rejection.
- •Patients maintained on a peritoneal dialysis regimen.
- •Patients who in the opinion of the Investigator plan to start dialysis replacement therapy in the next 6 months.
- •Any comorbidity or condition that, in the opinion of the Investigator, is anticipated to prevent participation in at least 12 months of the study
- •Is not willing to comply with the contraceptive requirements during the study period, as described in study protocol.
- •Female patient is pregnant, planning a pregnancy, or breast feeding.
- •Has known active human immunodeficiency virus (HIV) infection; or evidence of current or chronic hepatitis C virus (HCV) or hepatitis B (HBV) infection.
- •Received an investigational agent within the last 30 days or 5 halflives, whichever is longer, prior to the first dose of study drug, or are in follow-up of another clinical study during Screening. Consultation with the Medical Monitor is required if treated with unapproved products prior to consent regardless of the time interval prior to the first dose of study drug.
- •Known history of allergic reaction to an oligonucleotide or GalNAc.
- •Diagnosis of conditions other than PH1 contributing to renal insufficiency such as glomerulonephritis, nephrotic syndrome, or lupus nephritis.
- •Any condition or comorbidity, which in the opinion of the Investigator, would make the patient unsuitable for dosing or would interfere with study compliance, data interpretation, patient safety, and/or patient participation in the study. This includes significant active and poorly controlled (unstable) cardiovascular, neurologic, gastrointestinal, endocrine, renal or psychiatric disorders unrelated to PH1 identified by key laboratory abnormalities or medical history.
- •Unwilling or unable to limit alcohol consumption throughout the course of the study. Alcohol intake of >2 units/day is excluded during the study (unit: 1 glass of wine [approximately 125 mL] = 1 measure of spirits [approximately 1 fluid ounce] = ½ pint of beer [approximately 284 mL].
- •History of alcohol abuse, within the last 12 months before screening, in the opinion of the investigator.
- •Patients with a previous liver transplant or for whom a liver transplant is anticipated in the next 6 months.
结局指标
主要结局
Cohort A: Percent change in plasma oxalate from Baseline to Month 6
Cohort A: Percent change in plasma oxalate from Baseline to Month 6
Cohort B: Percent change in plasma oxalate from Baseline to Month 6
Cohort B: Percent change in plasma oxalate from Baseline to Month 6
次要结局
- Primary Analysis Period (Baseline to 6 months): Percent change in plasma oxalate AUC between dialysis sessions (Cohort B)
- Absolute change in plasma oxalate
- Change in the following parameters: *Urinary oxalate measured by percent and absolute change in 24-hour urinary oxalate excretion corrected for body surface area (BSA) and spot urinary oxalate:creatinine ratio, when available *QoL assessed by the PedsQL Total Score for patients ≥2 to <18 years of age at consent, and as assessed by KDQOL Burden of Kidney Disease and Effect of Kidney Disease on Daily Life subscales, and SF-12 Physical Component Summary and Mental Component Summary, in patients ≥18
- Plasma PK parameters of lumasiran
- Percent change in plasma oxalate AUC between dialysis sessions (Cohort B)
- Percent and absolute change in plasma oxalate
- Change in the following parameters: *Nephrocalcinosis as assessed by renal ultrasound; *Frequency and mode of dialysis (Cohort B); *Frequency of renal stone events; *Urinary oxalate measured by 24-hour urinary oxalate excretion corrected for BSA, and spot urinary oxalate:creatinine ratio; *Renal function as assessed by estimated glomerular filtration rate (eGFR) (Cohort A); *Measures of systemic oxalosis in the following systems: -Cardiac -Skeletal -Ocular; *QoL(Quality of life) assessed
研究者
Clinical Trial Information Line
Scientific
Alnylam Pharmaceuticals Inc.
研究点 (4)
Loading locations...
相似试验
招募中
3 期
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events (V-PLAQUE)2024-511126-31-00Novartis Pharma AG173
招募中
2 期
LUSPARA - Luspatercept in patients affected with rare inherited anemias2024-520200-26-00Eurobloodnet Association45
招募中
2 期
Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations – ELEMENT2023-504925-38-00GBG Forschungs GmbH176
招募中
3 期
FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busulfan versus fludarabine/busulfan) in adults with acute myeloid leukemia and eligible to allogeneic stem cell transplantation: a SFGM-TC studyacute myeloid leukemia2022-502019-12-00Centre Hospitalier Universitaire De Nantes302
已完成
2 期
Basimglurant in children, adolescents, and young adults with TSC2024-512611-53-00Noema Pharma AG31